Evaluation of Diagnostic Efficiency of Alpha-Fetoprotein in Patients with Liver Cirrhosis and Hepatocellular Carcinoma: Single-Center Experience by Mehinovic, Lejla et al.
 _______________________________________________________________________________________________________________________________ 
1668                                                                                                                                                                                              https://www.id-press.eu/mjms/index 
 
ID Design Press, Skopje, Republic of Macedonia 
Open Access Macedonian Journal of Medical Sciences. 2018 Sep 25; 6(9):1668-1673. 
https://doi.org/10.3889/oamjms.2018.344 
eISSN: 1857-9655 
Clinical Science 
 
 
  
 
Evaluation of Diagnostic Efficiency of Alpha-Fetoprotein in 
Patients with Liver Cirrhosis and Hepatocellular Carcinoma: 
Single-Center Experience 
 
 
Lejla Mehinovic
1
, Erna Islamagic
1
*, Azra Husic-Selimovic
2
, Amina Kurtovic-Kozaric
3
, Zora Vukobrat-Bijedic
4
, Damir Suljevic
1
 
 
1
Department of Biology, Faculty of Science, University of Sarajevo, Sarajevo, Bosnia and Herzegovina; 
2
Clinic for 
Gastroenterohepatology, Clinical Center of the University of Sarajevo, Sarajevo, Bosnia and Herzegovina; 
3
Department of 
Clinical Pathology, Cytology and Human Genetics, Clinical Center of the University of Sarajevo, Sarajevo, Bosnia and 
Herzegovina; 
4
Polyclinic Al-Tawil, Sarajevo, Bosnia and Herzegovina 
 
Citation: Mehinovic L, Islamagic E, Husic-Selimovic A, 
Kurtovic-Kozaric A, Vukobrat-Bijedic Z, Suljevic D. 
Evaluation of Diagnostic Efficiency of Alpha-Fetoprotein in 
Patients with Liver Cirrhosis and Hepatocellular 
Carcinoma: Single-Center Experience. Open Access 
Maced J Med Sci. 2018 Sep 25; 6(9):1668-1673. 
https://doi.org/10.3889/oamjms.2018.344 
Keywords: AFP; Hepatocellular carcinoma; Liver 
cirrhosis 
*Correspondence: Erna Islamagic. Department of 
Biology, Faculty of Science, University of Sarajevo, 
Sarajevo, Bosnia and Herzegovina. E-mail: 
erna.islamagic@hotmail.com 
Received: 31-May-2018; Revised: 22-Aug-2018; 
Accepted: 28-Aug-2018; Online first: 24-Sep-2018 
Copyright: © 2018 Lejla Mehinovic, Erna Islamagic, Azra 
Husic-Selimovic, Amina Kurtovic-Kozaric, Zora Vukobrat-
Bijedic, Damir Suljevic. This is an open-access article 
distributed under the terms of the Creative Commons 
Attribution-NonCommercial 4.0 International License (CC 
BY-NC 4.0) 
Funding: This research did not receive any financial 
support 
Competing Interests: The authors have declared that no 
competing interests exist 
 
Abstract 
BACKGROUND: AFP serum levels are considered as diagnostic and specific for hepatocellular carcinoma (HCC) 
in patients with liver cirrhosis (LC). 
AIM: This study aimed to examine the diagnostic value of AFP in the distinguishing of patients with HCC from 
patients with LC, and to analyse the potential correlation between AFP levels and liver disease stages. 
MATERIAL AND METHODS: Fifty patients with LC and fifty patients with HCC were included in this study. The 
majority of the patients were males, while the HBV aetiology was dominant. 
RESULTS: Significant differences between LC and HCC patients were detected for AST, ALT, GGT, bilirubin, 
AFP and AP. Patients with HCC had higher AFP values compared to LC. There was no significant correlation 
between the size of the tumour lesion and serum AFP levels. A positive correlation between AFP concentration 
and GGT activity was determined, as was the negative correlation between AFP and age of the subjects. The 
AFP value of 23.34 ng/m showed high sensitivity (84%) and specificity (82%). 
CONCLUSION: The size of the surface below the ROC curve (AUC) was 0.877 (0.80-0.95), which makes AFP a 
good biomarker and this diagnostic test is sufficient to separate patients with HCC and LC. 
 
 
 
 
 
 
Introduction 
 
Hepatocellular carcinoma (HCC) is a 
malignant epithelial neoplasm with hepatocellular 
differentiation, and it is the most common primary 
malignant liver neoplasm [1]. HCC is ranked sixth in 
the world among all malignant neoplasms, and due to 
its rapid progression and poor outcomes it is ranked 
third regarding mortality from malignant neoplasms: 
among men, it is the fifth most common malignancy 
and the third most common the cause of death from 
malignant neoplasms [1] [2]. Men are three times 
more likely than women to develop HCC, which is 
ranked as the eight most common type of cancer [1]. 
Over the past 20 to 30 years, the occurrence of newly 
diagnosed HCC has more than doubled in the United 
Kingdom and the United States, and the mortality rate 
will rise by 14% among men in the UK for the next 20 
years [1] [2] [3].
 
The cause of higher incidence is an increase 
in the number of HCV infections as well as migration 
from regions where HBV is highly represented, such 
as developing countries, which is also considered to 
be a biological carcinogen [4] [5]. The risk for HCC 
disease was additionally increased in patients with 
higher levels of HBV replication, indicating the 
presence of hepatitis B antigen (HBeAg) and high 
levels of HBV DNA [6] [7] [8].
 
Many studies pointed out serum levels of AFP 
and GGT as significant prognostic factors in predicting 
the prognosis of HCC patients [9] [10]. Several studies 
have shown that younger patients with diagnosed 
HCC have higher levels of serum AFP compared to 
older patients with the same pathological condition 
[11] [12] [13]. Furthermore, recent studies have shown 
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that high serum AFP concentration correlates with 
poor prognosis in patients with HCC. According to 
previous studies, elevated serum concentrations of 
AFP in patients with LC are a risk factor for the 
development of HCC because increased AFP 
production in patients with LC is a reflection of large 
and abnormal hepatic regeneration [14] [15].
 
AFP serum levels > 400 ng/ml are considered 
as diagnostic and specific for HCC in patients with 
liver cirrhosis [16]. According to Gomez Senenta et 
al., the high specificity of AFP that can be obtained by 
increasing its diagnostic thresholds and allows the use 
of this biomarker as a confirmatory test for the 
diagnosis of HCC [17]. Furthermore, previous studies 
have shown that AFP values > 200 ng/ml in patients 
with cirrhosis of HBV and/or HCV etiology are highly 
predictive for HCC indicating that using higher serum 
AFP concentration as a limit value of the diagnostic 
test progressively reduces the number of detected 
HCC cases, i.e. reduces its sensitivity, but in favor of 
its specificity [18] [19] [20] [21] [22] [23].
 
This study aimed to examine the diagnostic 
value of alpha-fetoprotein in the distinguishing of 
patients with HCC from patients with liver cirrhosis, 
i.e. to determine its sensitivity and specificity in the 
detection of hepatocellular carcinoma in the examined 
sample. Additionally, the aim was to analyse the 
potential correlation between AFP levels and liver 
disease stages. 
 
 
Material and Methods  
 
In this study 100 patients (57 men and 43 
women) were included and categorised into two 
groups. The first group (n = 50) consisted of patients 
with diagnosed liver cirrhosis (LC) of HBV and /or 
HCV viral aetiology, and the average age of patients 
was 62.70 ± 10.49 years. The second group consisted 
of patients (n = 50) with proven hepatocellular 
carcinoma (HCC), and the average age of patients 
was 63.76 ± 10.92 years. In all patients, total bilirubin 
and AFP (alpha-fetoprotein) concentrations, AST 
(aspartate aminotransferase), ALT (alanine 
aminotransferase), γGT (gamma-glutamyl 
transferase), AP (alkaline phosphatase) activity were 
analysed. Biochemical parameters were analysed 
using the VITROS 5600 Integrated System (Ortho-
Clinical Diagnostics, USA) analyser and 
chemiluminescent microparticle immunoassay 
ARCHITECT AFP assay (CMIA, Ireland) was used for 
AFP detection. EHO and computerised tomography 
(CT) were used to detect and measure the size of this 
lesion (HCC). 
All data were analysed using IBM SPSS 
Statistics ver. 20 (USA). Variance analysis (ANOVA) 
was used to test differences. Survival Kaplan-Meier 
test was used to analyse the coherence between 
sensitivity and specificity through all possible limit 
values that determine the positive pathological 
condition or presence of the disease. The area under 
the ROC curve (AUC) is the measure of the 
discriminating power of the diagnostic test. 
 
 
Results 
 
The percentage of patients diagnosed with LC 
and HCC, patients' sex and age, aetiology of disease 
(HCV, HBV) and significant differences (p values) are 
presented in Table 1. The group of patients with a 
diagnosis of liver cirrhosis (LC) had 50 patients (26 
males and 24 women), the average age of 62.70 
years. In the HCC group (n = 50) consisted of 31 
males and 19 women average age was 63.73 years. 
No significant differences were found between men 
and women when comparing both diseases; also no 
significant difference in age and viral aetiology was 
established. HBV is a dominant viral agent present in 
62% of the patients. 
Table 1: Demographic and clinical characteristics of patients 
with LC and proven HCC 
Characteristics 
Patients with 
LC
1
 
Patients with 
HCC
2
 
Total p values 
Gender 
Males 26 or 52 % 31 or 62 % 57 > 0.05 
Females 24 or 48 % 19 or 38 % 43 > 0.05 
Age 
Mean 62.70±10.49 63.73±10.92 63.29±10.67 > 0.05 
Range 30-81 29-81 29-81 - 
Etiology 
HBV
3 
28 or 56 % 34 or 68 % 62 > 0.05 
HCV
4 
21 or 42 % 16 or 32 % 37 > 0.05 
HBV+HCV 1 or 2 % - 1 - 
1
LC - liver cirrhosis; 
2
HCC - hepatocellular carcinoma; 
3
HBV- hepatitis B virus; 
4
HCV-
hepatitis C virus. 
 
Table 2 shows the values of biochemical 
parameters in LC and HCC patients, and significant 
differences between them. All patients had high 
values of biochemical parameters compared to the 
reference range, while HCC patients had higher 
values compared to LC patients. Significant 
differences between these two groups were observed 
for AST, GT, AP and AFP values. 
Table 2: Differences in biochemical parameters in LC and HCC 
patients 
Parameters  Patients with LC
1 
(n = 50) Patients with HCC
2
 (n = 50) P values 
Total bilirubin  43.63 ± 34.17 60.82 ± 99.41  0.05 
AST 109.24 ± 145.02 160.42 ± 138.48  0.05* 
ALT 75.50 ± 91.57 78.08 ± 60.77  0.05 
GT 110.98 ± 163.67 192.74 ± 188.47  0.05* 
AP 123.00 ± 88.03 199.56 ± 149.47  0.05* 
AFP 256.82 ± 1634.03 9129 ± 17547.01  0.05* 
* Significant differences at the level of 0.05. 
 
Table 3 shows AFP serum concentrations in 
LC and HCC patients. Also, AFP values for HCC 
patients with viral aetiology were presented as well as 
Spearman correlation between AFP and age of 
patients. Males in the group of LC and HCC patients 
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had significantly higher values compared to females. 
Among HCC patients, very high values of AFP 
(12465.08 ng/l) were determined for patients with HBV 
aetiology in comparison to patients with HCV 
aetiology, but these differences were not significant. A 
negative correlation (-0.053) but not statistically 
significant was found between the serum levels of 
AFP concentration and age of the patient (younger 
patients had more serum AFP values). 
Table 3: Differences in serum concentrations of AFP according 
to aetiology and gender 
Diagnosis HBV/HCV Mean ± SD p values Correlation between 
AFP and age HCC patients 
(Males/females) 
HBV 12465.08  0.05 
HCV 2040.92 
-0.053 
HCC patients Males 10790 ± 19757.43  0.05 
Females  6419 ± 13231.46 
LC patients Males  468.60 ± 2265.50  0.05 
Females  27.40 ± 62.82 
 
Table 4 shows the distribution of serological 
AFP values between LC and HCC patients. Both 
groups had a very high percentage of patients with 
increased serum AFP (> 7 ng/ml). Only 8% of HCC 
patients had serum AFP values within the reference 
range. 
Table 4: Distribution of serological AFP values between LC and 
HCC patients 
AFP concentrations LC patients HCC patients Total 
> 7 ng/ml 32 or 64 % 46 or 92 % 78 % 
 7 ng/ml 18 or 36 % 4 or 8 % 22 % 
 
The sensitivity of the medical diagnostic test 
(true positive rate) gives the ability to detect the 
presence of the disease; however, the specificity of 
the medical diagnostic test (true negative rate) gives 
the ability to determine the absence of the disease. 
The ROC curves show the relationship between 
sensitivity and 1-specificity through all possible limit 
values that determine the positive pathological 
condition or presence of the disease. The area below 
the ROC curve (AUC) is the measure of the 
discriminating power of the diagnostic test [24].
 
 
Figure 1: ROC curve of serum alpha-fetoprotein for the diagnosis of 
hepatocellular carcinoma. The green line corresponds to the 1:1 
correlation between two parameters 
The ROC curve (receiver-operating 
characteristic curve) is, therefore, a graphical 
representation of the proportion of successfully 
identified and falsely identified cases of hepatocellular 
carcinoma. Figure 1 shows an AUC of 0.877 (0.80-
0.95), making this biomarker a good distinguishing 
parameter for patients with HCC and those with LC. 
Table 5 shows AUC values for ROC curve. 
Also, ROC analysis implies testing all AFP serum 
values, and for each of the sensitivity and specificity 
were detected. It has been determined that the 
optimal limit value of AFP serum concentrations for 
distinguishing of patients (with and without HCC) 
within our population was 23.34 ng/ml. At this serum 
concentration, this test has approximate and high 
sensitivity and specificity (84% vs 82%) indicating the 
diagnostic significance of this tumour marker for early 
diagnosis of hepatocellular carcinoma in LC patients. 
Table 5: Area of measurements under ROC curves (AUC), AFP 
sensitivity and specificity 
Variable AUC 
STD 
Error
1 
Asympt 
sig.
2 UCL LCL Cut-off Sens. Specify. 
AFP 0.877 0.038 0.000 0.802 0.0952 23.34 84% 82% 
1 
Under a non-parametric assumption; 
2 
Null hypothesis: true area = 0.5; UCL – upper 
control limit; LCL – lower control limit; Sens. – sensitivity; Spec. – specificity; Optimal cut-
off: optimal limit value. 
 
Since our limit value has similar sensitivity 
and specificity, the limit values with the best 
performance regarding sensitivity and specificity are 
shown in Table 6. 
Table 6: Specificity and sensitivity of the different AFP limit 
values for the diagnosis of hepatocellular carcinoma 
AFP (ng/ml) Sensitivity % Specificity % 
6.27 92 % 34 
12.38 88 60 
19.14 84 76 
58.49 80 90 
81.58 78 94 
149.77 74 94 
219.96 72 98 
341.70 70 98 
420.67 66 99 
 
Table 7 shows a grouping of patients with 
HCC in comparison to tumour lesion size and serum 
AFP level. 
Table 7: Tumor size in HCC patients and correlation of AFP 
about lesion size 
Tumour size (cm) N (%) AFP (ng/ml) 
  ≤ 20 21-399 ≥ 400 
 3 2 or 4 % 1 1 0 
3-5 11 or 22 % 1 3 7 
 5 37 or 74 % 6 4 27 
 
According to the results shown in Table 7, 37 
patients with proven HCC (74%) had a tumour> 5 cm, 
and six patients had normal serum AFP levels, four 
moderately elevated, and 27 patients with tumour size 
> 5 cm had significantly elevated values serum AFP. 
In the group of 11 patients (22%) with proven HCC 
with tumour size from 3-5 cm, one patient had a 
normal serum AFP level, in three patients this 
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biomarker was moderately elevated and in 7 patients 
it was elevated (≥ 400 ng/ml). Only two patients (4%) 
with proven HCC had tumour size < 3 cm; one of them 
had a normal serum AFP level, and the other one had 
moderately elevated AFP concentration. 
 
Discussion 
 
Our research has shown a higher percentage 
of male patients with LC and HCC diagnosis, while the 
average age is not different in comparison to women. 
Most patients had HBV viral aetiology with dominant 
prevalence in our country [25]. Patients with 
hepatocellular carcinoma developed after HBV 
infection have significantly higher mean levels of AFP 
than patients with proved hepatocellular carcinoma 
developed in the background of HCV infection. 
Therefore, a type of viral infection affects serum levels 
of alpha-fetoprotein in patients with hepatocellular 
carcinoma. 
Due to more progressive disease, HCC 
patients had higher values of all analysed parameters 
compared to LC patients. The largest variations were 
detected for AFP concentrations. The serological 
values of AFP and GT correlate, as previously 
confirmed in the study of Ertle et al., [26]. This 
correlation shows parallel reexpression of AFP with 
reexpression of GT during the development of HCC, 
otherwise present in embryonic liver and suppressed 
after birth. Younger patients tend to have higher levels 
of serum AFP compared to older patients [12]. The 
results of our study showed a significant reverse 
correlation between serum AFP levels and age of 
patients. 84% of our patients with HCC had an 
elevated level of this biomarker, similar to results in 
previous studies [27] [28].
 
This is the first study in Bosnia and 
Herzegovina that by analysing the ROC curve 
evaluates the diagnostic performance of serological 
tests. The AUC value > 0.96 suggests, an excellent 
discriminatory ability of the diagnostic test [29]. In our 
study, measurement of AFP has shown a significant 
ability to discriminate between HCC and LC diagnosis 
due to its AUC that was very close to the specified 
value. In previous studies, the ROC curve of the 
alpha-fetoprotein used as a diagnostic test suggests 
that the serum AFP level of about 20 ng/ml provides 
the optimal balance between sensitivity and specificity 
(optimal cut-off/limit value). According to Trevisiani et 
al., the best diagnostic cut-off serum AFP level ranged 
from 16 to 20ng/ml, with a high specificity of 89.4% 
and a sensitivity of 60% [30]. In our case, this 
diagnostic test has omitted 40% of HCC cases. If a 
higher limit value were used, it would progressively 
reduce the number of detected HCC cases, i.e. would 
reduce the sensitivity of the diagnostic test. Recent 
results of Daruzo et al. and El-Hussein et al. indicated 
a sensitivity of 69% and 68.2% at the limit of 19.2 
ng/ml in the first and 25 ng/ml in the second study [31] 
[32].
 
Our research has confirmed results from 
earlier studies where the best sensitivity and 
specificity balance of the AFP serum level was at the 
value of 20 ng/ml; in our case, it was 23.34 ng/ml. 
Optimal AFP serum level for our study had a high 
sensitivity of 84% and specificity of 82%. This value of 
sensitivity was higher than values obtained by Arietta 
et al. where the optimal cut-off value at 21ng/ml had a 
76% of sensitivity [33]. However, our sensitivity (84%) 
and specificity (82%) values were within sensitivity, 
and specificity ranges from 39% to 97%, and 76% to 
95%, respectively, and they are similar to the results 
from previous studies [19] [20] [21] [22] [23]. However, 
our results regarding the sensitivity and the specificity 
of the optimal AFP limit value were more favourable in 
comparison to results reported by Trevisiana et al., 
Durazo et al., El-Hussain et al. and Hernandez et al., 
which were taken as reference in current scientific 
frameworks in this field [18] [30] [31] [32]. One 
explanation for this phenomenon would be that in our 
study only patients with viral aetiology were involved, 
whereas in the mentioned studies viral aetiology was 
dominant but not excluded. Accordingly, this 
biomarker has significantly better performance in 
hepatocellular carcinoma with viral aetiology 
compared to other HCC etiologies, as it was 
demonstrated in the recent study by Ertel et al., [26]. 
The surface area under the ROC curve (AUC) was 
0.877 (0.80-0.95), making this biomarker a good 
diagnostic test for distinguishing HCC and LC 
patients.  
In the case of our patients, the value of 0.877 
is at the very limit so that a diagnostic test could be 
characterised as excellent, given this value was close 
to 0.90. Our results were similar to results obtained by 
Trevisiani et al., where AFP serum concentrations 
higher than 20 ng/ml had a specificity of 98.4% or less 
than 2 % of patients without HCC had serological AFP 
levels higher than 20 ng/ml [30]. Also, the results from 
our study confirmed previous serum levels of AFP > 
400 ng/ml as diagnostic, highly specific for HCC, i.e. 
that 1% or less of our patients had high AFP 
concentrations and did not have HCC [34]. It is 
important to note that high limit value is not useful for 
detecting early stage of HCC [34]. In these cases, 
patients with primary liver cancer may have normal 
levels of serum AFP; however normal or moderately 
elevated AFP levels do not exclude the HCC 
diagnosis. 
We found that 74% of HCC patients had 
tumour lesion size more than > 5 cm as it was 
reported earlier by Arietta et al., (75%) [33]. However, 
previous studies have found that two-thirds of patients 
with hepatocellular lesion size < 4 cm have serum 
AFP levels < 200 ng/ml. Also, it has been reported 
that up to 20% of HCC patients do not produce 
elevated levels of AFP [35]. These data are consistent 
with the results of our study where 16% of HCC 
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patients did not have elevated levels of AFP. Although 
it may be inferred that smaller tumour size is related 
with lower serum AFP concentrations in comparison 
to tumours with larger diameter, our results showed 
that there was no significant correlation between the 
size of the tumour lesion and the level of AFP, which 
is similar to results from previous studies except in 
case of results obtained by Abbasi et al. who have 
established the existence of correlation [36] [37]. The 
absence of correlation between the serum 
concentration and the size of the hepatocellular lesion 
could be explained by the fact that tumour 
differentiation and its AFP secretion ability are more 
important in determining the level of serum AFP 
produced by primary liver cancer, than tumour size. 
Adequate sensitivity and specificity allow the 
use of serum AFP values as an extremely useful tool 
in preclinical HCC detection in liver cirrhosis patients. 
We believe that the results of our research gave a 
complete picture of the role of AFP in HCC 
pathogenesis and suggested the justification of using 
this parameter in determination and monitoring.  
Serum levels of liver biomarkers are 
significantly higher in HCC patients compared to LC 
patients. The serum AFP level could not be used as a 
reliable indicator of tumour lesion size; tumour 
differentiation and its AFP secretion ability are more 
important for determining serum AFP levels produced 
by primary liver cancer than its size alone. The size of 
the AUC under ROC curve of 0.877 suggests that the 
determination of AFP serological concentration may 
be considered as a good diagnostic test for the 
distinguishing patients with hepatocellular carcinoma 
and those with cirrhosis (with viral B and C aetiology). 
Based on the obtained ROC curve, the optimal serum 
concentration of AFP for discrimination between 
patients with and without HCC within our population 
was 23.34 ng/ml. This value achieved a balance of 
sensitivity and specificity of the serum AFP level, used 
as a diagnostic test. 
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